TOCA News and Press, Tocagen From 11/07/18

SAN DIEGO , Nov. 7, 2018 /PRNewswire/ --  Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced that Marty Duvall , chief executive officer, will present at the following upcoming investor conferences: Wednesday, November ...

SAN DIEGO , Nov. 6, 2018 /PRNewswire/ --  Tocagen Inc. (Nasdaq: TOCA ), a clinical-stage, cancer-selective gene therapy company, today announced three presentations of updated clinical and preclinical data at the Society for Immunotherapy of Cancer (SITC) 33 rd Annual Meeting &am...

SAN DIEGO , Nov. 1, 2018 /PRNewswire/ --  Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced it will report its third quarter 2018 financial results and business progress on Thursday, November 8, 2018, after the close of the U....

In oncology, there are a few forms of cancer that get regarded for their grave prognoses. Not that you ever want to get any kind of cancer, but certain tumors have been particularly resistant to treatment advances over the years. Glioblastoma is a hallmark of this class of "difficult-to-treat"...

SAN DIEGO , Sept. 19, 2018 /PRNewswire/ -- Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced that it has completed the planned enrollment of 380 patients in the global Toca 5 pivotal Phase 3 trial approximately three months ahead of sc...

Adverum Biotechnologies (NASDAQ: ADVM ) initiated with Buy rating and $11 (80% upside) price target at SunTrust. Shares up  2%  premarket. More news on: Adverum Biotechnologies, Inc., Glaukos, Tocagen Inc, Healthcare stocks news, Stocks on the move, , Read more ...

SAN DIEGO , Aug. 28, 2018 /PRNewswire/ --  Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced that Marty Duvall , chief executive officer, will participate in a panel discussion titled, "Chinese Capital Meets Western Innovation" on...

SAN DIEGO , Aug. 23, 2018 /PRNewswire/ -- Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced the Toca 5 pivotal Phase 3 trial continues without modification following a planned first interim analysis of data conducted by an Independent ...